Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
UTP23 is a nucleolar protein that is a structural component of the small subunit (SSU) processome, which mediates early steps in the biogenesis of the 40S ribosomal subunit. It contains a degenerate PIN domain and a unique CCHC-type Zn finger motif, but lacks canonical nuclease activity, functioning instead as a structural factor in ribosome assembly. UTP23 associates specifically with snR30 snoRNA and is required for early processing of 18S rRNA at key cleavage sites (A0, A1, A2). It is evolutionarily conserved, essential for proper cell growth and ribosome maturation, but not considered a druggable or clinical therapeutic target. While implicated in the pathology of colorectal adenocarcinoma, it is not a primary disease gene or biomarker in current medical use.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on rRNA-processing protein UTP23 homolog (UTP23).